Omada Health (NASDAQ:OMDA) Price Target Raised to $28.00

Omada Health (NASDAQ:OMDA) had its price target raised by analysts at Needham & Company LLC from $26.00 to $28.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 33.97% from the company’s previous close.

Other analysts also recently issued reports about the stock. Barclays increased their price target on shares of Omada Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Omada Health in a report on Wednesday, October 8th. Evercore ISI set a $27.00 price target on Omada Health in a research report on Wednesday, October 8th. Canaccord Genuity Group upped their price target on Omada Health from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Finally, Baird R W upgraded Omada Health to a “hold” rating in a research note on Friday, September 5th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.00.

Omada Health Stock Performance

Shares of NASDAQ:OMDA traded down $0.97 during trading on Friday, hitting $20.90. The stock had a trading volume of 229,585 shares, compared to its average volume of 569,775. The company has a fifty day moving average of $23.77. Omada Health has a 12 month low of $14.14 and a 12 month high of $28.40.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.21. The firm had revenue of $68.03 million during the quarter, compared to analysts’ expectations of $61.15 million. Omada Health has set its FY 2025 guidance at EPS.

Institutional Trading of Omada Health

A number of large investors have recently made changes to their positions in the stock. Strs Ohio purchased a new position in shares of Omada Health during the third quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new stake in Omada Health in the 2nd quarter worth approximately $32,000. Rakuten Investment Management Inc. purchased a new stake in Omada Health during the 3rd quarter valued at $49,000. JPMorgan Chase & Co. purchased a new stake in Omada Health during the 3rd quarter valued at $82,000. Finally, Rhumbline Advisers bought a new position in shares of Omada Health during the 3rd quarter valued at $176,000.

About Omada Health

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.